You are an executive at one of the top drug companies in the United States. At the most recent product development meeting, two teams of scientists reported that each is within one year of having a new drug ready for clinical trials. Team A is developing a drug to cure a rare but fatal bone disease. Team B is developing a drug to treat a common, non–life-threatening skin condition. To make the deadline, however, both teams need an additional $10 million in funding. You know that the company can afford to fund only one team. According to the product analysis, Team A’s drug will be expensive to produce and difficult to market and yield only modest profits. Team B’s drug has the potential to yield massive profits.